About this trial
This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of PSA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.
Eligibility criteria
Qualifiers
Prostate cancer patients treated with radical prostatectomy
Disqualifiers
1. Received neoadjuvant endocrine/chemotherapy before surgery;
2. Urine leakage after surgery (positive creatinine test of drainage fluid).
Trial design
Treatments tested in this trial
- Not listed